Market Research Report
Hepatitis D - Market Insights, Epidemiology and Market Forecast-2028
|Published by||DelveInsight Business Research LLP||Product code||534760|
|Published||Content info||100 Pages
Delivery time: 1-2 business days
|Hepatitis D - Market Insights, Epidemiology and Market Forecast-2028|
|Published: January 1, 2019||Content info: 100 Pages||
DelveInsight's 'Hepatitis D - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hepatitis D in the United States, EU5 (France, Germany, Italy, Spain and United Kingdom), Japan and China.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Hepatitis D from 2016 to 2028 segmented by eight major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to find best of the opportunities and assess underlying potential of the market.
Study Period: 2016-2028
The DelveInsight Hepatitis D market report gives the thorough understanding of Hepatitis D by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hepatitis D in the US, Europe and Japan and China.
The Hepatitis D epidemiology division provide the insights about historical and current patient pool and forecasted trend for each of the 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, prevalence by Severity (Fulminant, Acute & Chronic), Gender Specific prevalence, Age Specific prevalence and diagnosed cases] of Hepatitis-D in the 8MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2016-2028.
According to DelveInsight, total prevalent population of Hepatitis D in 8 major markets was estimated to be 10,546,938 in 2016.
This segment of Hepatitis D report encloses the detailed analysis of marketed drugs and late stage (Phase-III & Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There is no cure or vaccine for Hepatitis D and the current market is based on the use of antiviral nucleotide analogs, conventional interferon and off-label use of pegylated Interferon. There is not much progress in treatment methods for Hepatitis D after Interferons, only off-label use of pegylated Interferon has reduced the doses of conventional interferon from thrice a week to once a week. To overcome the shortcomings of current treatment market different companies are working robustly with promising drug candidates in different target areas to bring an effective therapy to the market.
Detailed chapters for all the upcoming therapies i.e., Pegasys (Hoffmann-La Roche), Pegylated interferon lambda 1a (Eiger Biopharmaceuticals Inc.), Myrcludex B (MYR Pharma), Lonafarnib (Eiger Bio-Pharmaceuticals), REP 2139-Ca (Replicor Inc.) etc., have been covered in the report.
The Hepatitis D market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of off-label therapies, marketed therapies and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Hepatitis D was estimated to be USD 656 Million in 2016, and is expected to increase at a CAGR of XX% from 2016-2028.
This section focusses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.